MR. CHENGDE WU, ACUPUNCTURIST
Acupuncture at Corporate Dr, Houston, TX

6420567, Jul 16, 2002

Sep 26, 1997

08/938325

Chengde Wu - Houston TX
Bore Gowda Raju - Sugarland TX
Timothy Kogan - Sugarland TX
Natalie Blok - Houston TX

Texas Biotechnology Corporation - Houston TX

C07D26104

548245, 514311, 514312, 514313, 514314, 514378, 514379, 514380, 548244, 548247

Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.

6342610, Jan 29, 2002

Nov 7, 1997

08/913331

Ming Fai Chan - San Diego CA
Chengde Wu - Houston TX
Bore Gowda Raju - Sugar Land TX
Timothy Kogan - Sugar Land TX
Erik Joel Verner - Foster City CA
Rosario Silvestre Castillo - San Diego CA
Venkatachalapathi Yalamoori - San Diego CA
Adam Kois - San Diego CA

Texas Biotechnology Corp. - Houston TX

C07D20736

548543, 514421, 514441, 514470, 548550, 549 65, 549470

Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

6683103, Jan 27, 2004

Dec 20, 2001

10/029561

Chengde Wu - Houston TX
Natalie Blok - Houston TX
Timothy Kogan - late of Escondido CA
Karin Keller - Austin TX

Texas Biotechnology Corporation - Houston TX

A61K 3142

514378, 548247, 424451, 424464, 424489, 424493

Thienylsulfonamides and their pharmaceutically acceptable derivatives, pharmaceutical compositions, articles of manufacture, combinations, lyophilized powders and methods for the treatment of endothelin diseases using these formulations and sulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.

6432994, Aug 13, 2002

Mar 27, 2000

09/403599

Chengde Wu - Houston TX
Natalie Blok - Houston TX
Timothy Kogan - late of Escondido CA
Karin Keller - Houston TX
Patricia Woodard - Escondido CA

Texas Biotechnology Corporation - Houston TX

A61K 3142

514380, 548245, 548246, 548247

Thienyl-, furyl- and pyrrolyl-sulfonamides, pharmaceutically-acceptable salts of sulfonamides, formulations of salts and the sulfonamides, and methods for modulating or altering the activity of the endothelin family of peptides using the formulations and sulfonamides are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides are provided. A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.

2003020, Nov 6, 2003

May 28, 2003

10/447763

Chengde Wu - Houston TX, US
Bore Raju - Sugarland TX, US
Timothy Kogan - Sugarland TX, US
Natalie Blok - Houston TX, US
Patricia Woodard - Sugarland TX, US

C07D207/28, C07D333/32, C07D307/02

548/534000, 549/062000, 549/475000

Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.

6248767, Jun 19, 2001

Sep 26, 1997

8/938444

Natalie Blok - Houston TX
Chengde Wu - Houston TX
Patricia Woodard - Sugarland TX
Karin Keller - Houston TX
Timothy Kogan - Sugarland TX

Texas Biotechnology Corp. - Houston TX

A61K 3142, C07D26104

514380

Formulations of pharmaceutically-acceptable salts of thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides using the formulations are provided. In particular, formulations of sodium salts of N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamide salts for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide salt are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamide salts or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

6331637, Dec 18, 2001

Mar 22, 1999

9/274280

Ming Fai Chan - San Diego CA
Chengde Wu - Houston TX
Bore Gowda Raju - Sugar Land TX
Timothy Kogan - Sugar Land TX
Adam Kois - San Diego CA
Erik Joel Verner - Foster City CA
Rosario Silvestre Castillo - San Diego CA
Venkatachalapathi Yalamoori - San Diego CA

Texas Biotechnology Corporation - Houston TX

C07D26110, A61K 31422, A61K 31423

548241

N-alkyl, N-alkenyl, N-alkynyl, N-aryl and N-fused bicyclo or tricyclo thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, (phenyl) and (phenoxy)thienylsulfonamides, (phenyl) and (phenoxy)furylsulfonamides, and (phenyl) and (phenoxy)pyrrolylsulfonamides and methods of using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

5783705, Jul 21, 1998

Apr 28, 1997

8/847797

Natalie Blok - Houston TX
Chengde Wu - Houston TX
Karin Keller - Houston TX
Timothy P. Kogan - Sugarland TX

Texas Biotechnology Corporation - Houston TX

C07D26106, C07D26114, C07D26104

548247

A process of preparing an alkali metal salt of a hydrophobic sulfonamide is provided. The process includes the step of dissolving a free sulfonamide in an organic solvent in the presence of a saturated alkali metal salt solution and recovering the formed sulfonamide salt from the organic phase.

6194448, Feb 27, 2001

Oct 14, 1999

9/417857

Ronald J. Biediger - Houston TX
Vanessa O. Grabbe - Sugar Land TX
George W. Holland - North Caldwell NJ
Jamal M. Kassir - Houston TX
Timothy P. Kogan - late of Escondido CA
Shuqun Lin - Huntingdon Valley PA
Robert V. Market - Pearland TX
Bore G. Raju - Fremont CA
Ian L. Scott - Albany NY
Chengde Wu - Houston TX

Texas Biotechnology Corporation - Houston TX

A61K 3138, A61K 31425, C07D31744, C07D27730, C07D40500

514438

A method for the inhibition of the binding of. alpha. sub. 4. beta. sub. 1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and the use of such compounds either as above, or in formulations for the control or prevention of diseases states in which. alpha. sub. 4. beta. sub. 1 is involved.